CEL-SCI Co. (NYSEAMERICAN:CVM) shares traded down 6.7% during trading on Thursday . The stock traded as low as $7.55 and last traded at $7.56, 764,215 shares changed hands during mid-day trading. An increase of 5% from the average session volume of 728,072 shares. The stock had previously closed at $8.10.
CEL-SCI (NYSEAMERICAN:CVM) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.19) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.07). The firm had revenue of $0.15 million during the quarter, compared to analysts’ expectations of $0.10 million.
Several institutional investors and hedge funds have recently added to or reduced their stakes in CVM. Thoroughbred Financial Services LLC bought a new stake in shares of CEL-SCI in the fourth quarter worth about $32,000. Bank of New York Mellon Corp bought a new stake in shares of CEL-SCI in the fourth quarter worth about $38,000. Mercer Global Advisors Inc. ADV bought a new stake in shares of CEL-SCI in the first quarter worth about $42,000. Finally, BlackRock Inc. grew its stake in shares of CEL-SCI by 5.0% in the fourth quarter. BlackRock Inc. now owns 634,031 shares of the company’s stock worth $1,820,000 after purchasing an additional 30,117 shares during the last quarter.
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.
Further Reading: What is a CD ladder?
Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.